Sökning: WFRF:(Gopinathan Aarthi)
> (2022) >
Method To Visualize...
Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multimodal Imaging
-
- Strittmatter, Nicole (författare)
- AstraZeneca, R&D, Clin Pharmacol & Safety Sci, Imaging & Data Analyt, Cambridge CB4 0WG, England
-
- Richards, Frances M. (författare)
- Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge CB2 0RE, England.;Astra Zeneca, Oncol R&D, Translat Med, Cambridge CB4 0WG, England
-
- Race, Alan M. (författare)
- Philipps Univ Marburg, Inst Med Bioinformat & Biostat, D-35032 Marburg, Germany
-
visa fler...
-
- Ling, Stephanie (författare)
- AstraZeneca, R&D, Clin Pharmacol & Safety Sci, Imaging & Data Analyt, Cambridge CB4 0WG, England
-
- Sutton, Daniel (författare)
- AstraZeneca, R&D, Clin Pharmacol & Safety Sci, Imaging & Data Analyt, Cambridge CB4 0WG, England
-
- Nilsson, Anna (författare)
- Uppsala universitet,Institutionen för farmaceutisk biovetenskap,Science for Life Laboratory, SciLifeLab
-
- Wallez, Yann (författare)
- Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge CB2 0RE, England.;AstraZeneca, Oncol R&D, Biosci, Cambridge CB2 0RE, England
-
- Barnes, Jennifer (författare)
- AstraZeneca, R&D, Clin Pharmacol & Safety Sci, Imaging & Data Analyt, Cambridge CB4 0WG, England
-
- Maglennon, Gareth (författare)
- AstraZeneca, R&D, Clin Pharmacol & Safety Sci, Imaging & Data Analyt, Cambridge CB4 0WG, England
-
- Gopinathan, Aarthi (författare)
- Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge CB2 0RE, England
-
- Brais, Rebecca (författare)
- Cambridge Univ Hosp NHS Trust, Cambridge CB2 0QQ, England
-
- Wong, Edmond (författare)
- AstraZeneca, R&D, Biol Engn, Cambridge CB12 6GH, England
-
- Serra, Maria Paola (författare)
- AstraZeneca, R&D, Clin Pharmacol & Safety Sci, Imaging & Data Analyt, Cambridge CB4 0WG, England
-
- Atkinson, James (författare)
- AstraZeneca, R&D, Clin Pharmacol & Safety Sci, Imaging & Data Analyt, Cambridge CB4 0WG, England
-
- Smith, Aaron (författare)
- AstraZeneca, Oncol R&D, DMPK, Cambridge CB2 0RE, England
-
- Wilson, Joanne (författare)
- AstraZeneca, Oncol R&D, DMPK, Cambridge CB2 0RE, England
-
- Hamm, Gregory (författare)
- AstraZeneca, R&D, Clin Pharmacol & Safety Sci, Imaging & Data Analyt, Cambridge CB4 0WG, England
-
- Johnson, Timothy, I (författare)
- Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge CB2 0RE, England
-
- Dunlop, Charles R. (författare)
- Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge CB2 0RE, England
-
- Kaistha, Brajesh P. (författare)
- Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge CB2 0RE, England.;AstraZeneca, Early Oncol, Clin IO Grp, Cambridge CBI2 6GH, England
-
- Bunch, Josephine (författare)
- Natl Phys Lab, Natl Ctr Excellence Mass Spectrometry Imaging, Teddington TW11 0LW, Middx, England.;Rosalind Franklin Inst, Didcot OX11 0QS, Oxon, England
-
- Sansom, Owen J. (författare)
- Canc Res UK Beatson Inst, Glasgow G61 1BD, Lanark, Scotland.;Univ Glasgow, Inst Canc Sci, Glasgow G61 1QH, Lanark, Scotland
-
- Takats, Zoltan (författare)
- Rosalind Franklin Inst, Didcot OX11 0QS, Oxon, England.;Imperial Coll London, Dept Metab Digest & Reprod, London SW7 2AZ, England
-
- Andrén, Per E., Professor, 1957- (författare)
- Uppsala universitet,Institutionen för farmaceutisk biovetenskap,Science for Life Laboratory, SciLifeLab
-
- Lau, Alan (författare)
- AstraZeneca, Oncol R&D, Biosci, Cambridge CB2 0RE, England
-
- Barry, Simon T. (författare)
- AstraZeneca, Oncol R&D, Biosci, Cambridge CB2 0RE, England
-
- Goodwin, Richard J. A. (författare)
- AstraZeneca, R&D, Clin Pharmacol & Safety Sci, Imaging & Data Analyt, Cambridge CB4 0WG, England.;Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow G12 8TA, Lanark, Scotland
-
- Jodrell, Duncan, I (författare)
- Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge CB2 0RE, England.;Univ Cambridge, Dept Oncol, Cambridge CB2 0XZ, England
-
visa färre...
-
AstraZeneca, R&D, Clin Pharmacol & Safety Sci, Imaging & Data Analyt, Cambridge CB4 0WG, England Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge CB2 0RE, England;Astra Zeneca, Oncol R&D, Translat Med, Cambridge CB4 0WG, England (creator_code:org_t)
- 2022-01-10
- 2022
- Engelska.
-
Ingår i: Analytical Chemistry. - : American Chemical Society (ACS). - 0003-2700 .- 1520-6882. ; 94:3, s. 1795-1803
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Gemcitabine (dFdC) is a common treatment for pancreatic cancer; however, it is thought that treatment may fail because tumor stroma prevents drug distribution to tumor cells. Gemcitabine is a pro-drug with active metabolites generated intracellularly; therefore, visualizing the distribution of parent drug as well as its metabolites is important. A multimodal imaging approach was developed using spatially coregistered mass spectrometry imaging (MSI), imaging mass cytometry (IMC), multiplex immunofluorescence microscopy (mIF), and hematoxylin and eosin (H&E) staining to assess the local distribution and metabolism of gemcitabine in tumors from a genetically engineered mouse model of pancreatic cancer (KPC) allowing for comparisons between effects in the tumor tissue and its microenvironment. Mass spectrometry imaging (MSI) enabled the visualization of the distribution of gemcitabine (100 mg/kg), its phosphorylated metabolites dFdCMP, dFdCDP and dFdCTP, and the inactive metabolite dFdU. Distribution was compared to small-molecule ATR inhibitor AZD6738 (25 mg/kg), which was codosed. Gemcitabine metabolites showed heterogeneous distribution within the tumor, which was different from the parent compound. The highest abundance of dFdCMP, dFdCDP, and dFdCTP correlated with distribution of endogenous AMP, ADP, and ATP in viable tumor cell regions, showing that gemcitabine active metabolites are reaching the tumor cell compartment, while AZD6738 was located to nonviable tumor regions. The method revealed that the generation of active, phosphorylated dFdC metabolites as well as treatment-induced DNA damage primarily correlated with sites of high proliferation in KPC PDAC tumor tissue, rather than sites of high parent drug abundance.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Radiologi och bildbehandling (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Radiology, Nuclear Medicine and Medical Imaging (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Strittmatter, Ni ...
-
Richards, France ...
-
Race, Alan M.
-
Ling, Stephanie
-
Sutton, Daniel
-
Nilsson, Anna
-
visa fler...
-
Wallez, Yann
-
Barnes, Jennifer
-
Maglennon, Garet ...
-
Gopinathan, Aart ...
-
Brais, Rebecca
-
Wong, Edmond
-
Serra, Maria Pao ...
-
Atkinson, James
-
Smith, Aaron
-
Wilson, Joanne
-
Hamm, Gregory
-
Johnson, Timothy ...
-
Dunlop, Charles ...
-
Kaistha, Brajesh ...
-
Bunch, Josephine
-
Sansom, Owen J.
-
Takats, Zoltan
-
Andrén, Per E., ...
-
Lau, Alan
-
Barry, Simon T.
-
Goodwin, Richard ...
-
Jodrell, Duncan, ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Radiologi och bi ...
- Artiklar i publikationen
-
Analytical Chemi ...
- Av lärosätet
-
Uppsala universitet